DNA Supramolecular Hydrogel-Enabled Sustained Delivery of Metformin for Relieving Osteoarthritis,ACS Applied Materials & Interfaces

当前位置： X-MOL 学术 › ACS Appl. Mater. Interfaces › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

DNA Supramolecular Hydrogel-Enabled Sustained Delivery of Metformin for Relieving Osteoarthritis
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2023-03-21 , DOI: 10.1021/acsami.2c20496
Chao Zhang _{1,

2} , Hong Huang _{1,

2} , Jianmao Chen _{1,

3} , Tingting Zuo ₄ , Qianhua Ou ₁ , Guangfeng Ruan ₅ , Jian He ₆ , Changhai Ding _{1,

7}

Affiliation

Osteoarthritis (OA) is a musculoskeletal disorder affecting ∼500 million people worldwide. Metformin (MET), as an oral hypoglycemic drug approved by the Food and Drug Administration, has displayed promising potential for treating OA. Nonetheless, in the articular cavity, MET suffers from rapid clearance and cannot circumvent the severe inflammatory environment, greatly confining the therapeutic efficacy. Herein, DNA supramolecular hydrogel (DSH) has been utilized as a sustained drug delivery vehicle for MET to treat OA, which dramatically prolonged the retention time of MET in the articular cavity from 3 to 14 days and simultaneously exerted a greater anti-inflammatory effect. Our delivery platform, termed MET@DSH, better protects cartilage than single-agent MET. Additionally, the corresponding molecular mechanisms underlying the therapeutic effects were also analyzed. We anticipate this DNA supramolecular hydrogel-enabled sustained drug delivery and anti-inflammatory strategy will reshape the current landscape of OA treatment.

中文翻译：

DNA 超分子水凝胶支持二甲双胍持续递送以缓解骨关节炎

骨关节炎 (OA) 是一种肌肉骨骼疾病，影响全球约 5 亿人。二甲双胍（MET）作为经美国食品和药物管理局批准的口服降糖药，在治疗 OA 方面显示出巨大的潜力。尽管如此，在关节腔内，MET清除速度快，无法避开严重的炎症环境，极大地限制了治疗效果。在此，DNA 超分子水凝胶 (DSH) 已被用作 MET 的持续药物递送载体来治疗 OA，这显着延长了 MET 在关节腔中的保留时间，从 3 天增加到 14 天，同时发挥了更大的抗炎作用。我们的交付平台，称为 MET@DSH，比单一代理 MET 更好地保护软骨。此外，还分析了相应的治疗作用的分子机制。我们预计这种 DNA 超分子水凝胶支持的持续药物递送和抗炎策略将重塑当前 OA 治疗的格局。

更新日期：2023-03-21

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南